Early Detection NeuraMetrix offers a passive, language- and education-agnostic digital biomarker from typing cadence to monitor brain health, presenting a sales opportunity to research institutions and healthcare providers seeking non-invasive cognitive assessment tools.

Research Collaboration The company has active collaborations with prestigious universities and foundations (e.g., Michael J. Fox Foundation, Stanford, Karolinska, UCSF), suggesting a track record that can be leveraged to engage additional research partners and expand trial programs.

Neurodegenerative Focus Current application areas include Parkinson’s, ADHD, multiple neurodegenerative and brain-related conditions, offering a entry point for sales conversations with clinics, universities, and pharma companies pursuing diagnostic tools and patient-monitoring solutions.

Growing Ecosystem With a small team and high-profile academic partnerships, there is potential to scale via partnerships, channel strategies, or white-label offerings to larger IT services firms looking to augment their health-tech portfolios.

Proof of Adoption A 90-day typing study involving Parkinson’s patients and healthy controls under MJFF collaboration demonstrates real-world data potential, enabling conversations around regulatory-grade data collection, longitudinal studies, and publication-ready outcomes.